Mark Foley, the former chairman and CEO of aesthetics leader Zeltiq, explains how the company maintained an innovative mind-set while stressing a stronger focus on execution and delivery.
Once he got the employees focused on creating and growing new markets, they got into a winning cycle and the business “really took off.” They expanded to more and more body parts and reduced treatment time by almost half.
When Foley assumed the CEO’s role, the company’s stock price hung in the single digits. Earlier this year, Allergan acquired Zeltiq for $2.48 billion, a deal worth more than $50 per share.
Foley is the recipient of the 2017 Medtech Conference Dealmaker of the Year Award.